Treatment Patterns and Prognostic Factors of Anti-HER2 Therapy in HER2-positive Advanced/Recurrent Gastric Cancer
Sustained anti-HER2 therapy was strongly associated with longer survival. Adjusting the cytotoxic partner to manage toxicity may help patients continue trastuzumab-based treatment and achieve better outcomes.
Authors
- Kotaro Yamashita (ORCID: https://orcid.org/0000-0001-9538-5705)
- Shigeto Nakai
- Hidetoshi Eguchi (ORCID: https://orcid.org/0000-0002-2318-1129)
- Noriko Wada (ORCID: https://orcid.org/0000-0002-8356-0163)
- Kota Momose
- Takuro Saito
- Takaomi Hagi
- YUKINORI KUROKAWA
- YUICHIRO DOKI
- TOMOKI MAKINO
- TSUYOSHI TAKAHASHI
- KOJI TANAKA
- TAROH SATOH
Institutions
- Osaka City University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.18001
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00